State-licensed 503A pharmacies can compound semaglutide for patient-specific prescriptions with documented clinical justification, such as an inactive-ingredient allergy or a dose not commercially available
The cardiovascular safety profile makes GLP-1 medications particularly attractive for people with diabetes who also have heart disease risk factors
Jos Morales, MD, a vascular neurologist and neurointerventional surgeon at Providence Saint Johns Health Center in Santa Monica, CA, also not involved in this review, told MNT that microglias effect on the neurovascular unit has been associated with dementia. He suggested that: [GLP-1 drugs] could potentially modulate inflammation to reduce the propensity for developing dementias such as Alzheimers disease, particularly in the setting of metabolic syndrome. Morales also explained that in people who have glycemia or type 2 diabetes, the inflammation of the blood-brain barrier can lead to progressive damage to the brain over longer periods. He noted that trials that combine neuroimaging techniques that measure the blood-brain barrier and GLP-1 treatment are needed and could prove that these drugs have neuroprotective benefits.
Here is the chain of events
Your medication is shipped discreetly to your door, along with easy-to-follow instructions to get you started
Seniors who are most medically motivated to start GLP-1 therapy those with severe obesity, established cardiovascular disease, or significant comorbidities are precisely the people who stand to gain the most from sustained treatment and who face the greatest health risk from abrupt discontinuation at the end of 2027
